View Older Stories View More Recent Stories

Aug 4, 2021 04:02PM Allogene Therapeutics Reports Second Quarter 2021 Financial Results
Aug 2, 2021 08:34AM Allogene Therapeutics (ALLO) Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
Aug 2, 2021 08:30AM Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
Aug 2, 2021 08:30AM Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
Jul 27, 2021 08:30AM Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021
Jul 27, 2021 08:30AM Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021
Jul 12, 2021 08:30AM Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
Jul 12, 2021 08:30AM Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
Jun 30, 2021 08:30AM Allogene Therapeutics (ALLO) Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma
Jun 30, 2021 08:30AM Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma
Jun 30, 2021 08:30AM Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma
Jun 21, 2021 07:05AM Allogene Therapeutics (ALLO) Appoints Shuyuan Yao as Allogene Overland Biopharm CEO
Jun 21, 2021 07:00AM Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer
Jun 4, 2021 09:00AM Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
Jun 4, 2021 09:00AM Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
May 20, 2021 08:30AM Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
May 20, 2021 08:30AM Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
May 19, 2021 04:53PM Allogene Therapeutics (ALLO) CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in R/R NHL and Plan to Initiate Pivotal Study in 2021
May 19, 2021 04:51PM Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021
May 19, 2021 04:51PM Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021
May 12, 2021 08:30AM Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021
May 12, 2021 08:30AM Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021
May 5, 2021 04:02PM Allogene Therapeutics Reports First Quarter 2021 Financial Results 
May 5, 2021 04:02PM Allogene Therapeutics Reports First Quarter 2021 Financial Results 
Apr 28, 2021 09:24AM Allogene Therapeutics (ALLO) to Present Data from its Anti-CD19 AlloCAR T Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
Apr 28, 2021 09:24AM Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
Apr 28, 2021 09:24AM Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
Apr 27, 2021 08:30AM Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021
Apr 27, 2021 08:30AM Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021
Apr 21, 2021 08:34AM Allogene Therapeutics (ALLO) Announces FDA RMAT Designation Granted to ALLO-715, an AlloCAR T Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma
Apr 21, 2021 08:30AM Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma
Apr 21, 2021 08:30AM Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma
Apr 19, 2021 08:36AM Allogene Therapeutics (ALLO) Granted IND Clearance from FDA for ALLO-605
Apr 19, 2021 08:30AM Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple M
Apr 19, 2021 08:30AM Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple M
Apr 12, 2021 08:34AM Allogene Therapeutics (ALLO), SpringWorks Therapeutics (SWTX) Report First Patient Dosing in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with R/R Multiple Myeloma
Apr 12, 2021 08:30AM Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multip
Apr 12, 2021 08:30AM Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multip
Apr 10, 2021 08:30AM Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Re
Apr 10, 2021 08:30AM Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Re
Feb 25, 2021 04:02PM Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Feb 25, 2021 04:02PM Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Feb 18, 2021 08:30AM Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Feb 18, 2021 08:30AM Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Feb 9, 2021 08:30AM Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
Feb 9, 2021 08:30AM Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
Jan 26, 2021 08:30AM Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine
Jan 26, 2021 08:30AM Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine
Jan 5, 2021 08:30AM Allogene Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Jan 5, 2021 08:30AM Allogene Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
View More Recent Stories View Older Stories